Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Dose-ranging, Multi-center, Single-blind, Double-dummy, Active-controlled Trial to Determine the Target Dose of Canakinumab (ACZ885) in the Treatment of Acute Flares in Gout Patients Who Are Refractory or Contraindicated to NSAIDs and/or Colchicine

NCT00798369 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00798369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00798369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Dose-ranging, Multi-center, Single-blind, Double-dummy, Active-controlled Trial to Determine the Target Dose of Canakinumab (ACZ885) in the Treatment of Acute Flares in Gout Patients Who Are Refractory or Contraindicated to NSAIDs and/or Colchicine
Lead sponsor
Novartis
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2008
Completion date
August 31, 2009
Enrollment
200 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

acute gout